Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR)

Historical Holders from Q1 2014 to Q3 2025

Symbol: ESPR on Nasdaq
Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 207M
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 108M
Holdings value: $286M
% of all portfolios: 0.001%
Grand Portfolio weight change: +0%
Number of holders: 188
Number of buys: 102
Number of sells: -55
Average Value change %: +0%
Average buys %: +0%
Average sells %: 0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Two Seas Capital LP	4.7%	-6%	$25.8M	-$544K	9.75M	-2.06%	Two Seas Capital LP	30 Sep 2025
BB BIOTECH AG	4.9%	-2%	$8.82M	-$228K	9.69M	-2.51%	BB Biotech AG	04 Mar 2025
WASATCH ADVISORS LP	3.5%	-33.3%	$18.7M	-$10.3M	7.06M	-35.4%	Wasatch Advisors LP	30 Sep 2025

Institutional Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	108M	$286M	+$32M	2.04M	1.7M	$2.65	188
2025 Q2	98.2M	$96.7M	-$21.2M	593K	137K	$0.98	161
2025 Q1	111M	$160M	-$24.3M	977K	248K	$1.44	183
2024 Q4	126M	$277M	+$4.39M	2.79M	3.38M	$2.20	188
2024 Q3	129M	$213M	-$19M	1.53M	2.35M	$1.65	181
2024 Q2	137M	$304M	+$17.7M	2.9M	5.5M	$2.22	173
2024 Q1	125M	$336M	+$141M	2.71M	4.91M	$2.68	147
2023 Q4	71.6M	$214M	-$13.2M	1.77M	5.72M	$2.99	127
2023 Q3	77.2M	$75.7M	-$1.73M	182K	1.1M	$0.98	120
2023 Q2	74.3M	$103M	-$10.5M	501K	1.82M	$1.39	121
2023 Q1	80.9M	$129M	-$22.1M	1.29M	3.65M	$1.59	161
2022 Q4	73.5M	$458M	+$39.2M	8.74M	35.7M	$6.23	164
2022 Q3	62.4M	$418M	+$53.3M	3.17M	14.3M	$6.70	143
2022 Q2	55.4M	$352M	+$24.3M	1.62M	6.45M	$6.36	128
2022 Q1	51.9M	$241M	-$10.7M	1.02M	3.54M	$4.64	121
2021 Q4	53.6M	$268M	+$97.3M	2.66M	2.2M	$5.00	119
2021 Q3	24.8M	$299M	-$61.5M	11M	6.24M	$12.05	133
2021 Q2	28.3M	$599M	-$18.9M	17.5M	7.58M	$21.15	140
2021 Q1	28.7M	$805M	-$64.5M	17.6M	5.51M	$28.05	151
2020 Q4	30.9M	$803M	-$34.2M	14.3M	9.37M	$26.00	152
2020 Q3	31.6M	$1.18B	-$28.8M	15.5M	23.3M	$37.17	165
2020 Q2	32M	$1.64B	+$124M	24.9M	27.8M	$51.31	179
2020 Q1	29.6M	$916M	+$54M	12.2M	7.91M	$31.53	157
2019 Q4	27.8M	$1.62B	+$45.9M	27.5M	36.2M	$59.63	170
2019 Q3	27M	$991M	-$72.2M	16.5M	16.1M	$36.66	145
2019 Q2	28.4M	$1.32B	+$217M	20.8M	22.7M	$46.52	166
2019 Q1	27.6M	$1.11B	+$27M	22.6M	13M	$40.15	160
2018 Q4	26.8M	$1.23B	-$65.8M	20.6M	28.9M	$46.00	152
2018 Q3	28.3M	$1.25B	-$107M	58.8M	31.3M	$44.37	151
2018 Q2	30.8M	$1.21B	+$133M	45.7M	13.4M	$39.19	151
2018 Q1	26.5M	$1.91B	+$178M	78.8M	75.2M	$72.33	184
2017 Q4	24M	$1.58B	+$28.5M	34.6M	32.7M	$65.84	163
2017 Q3	24.2M	$1.21B	+$158M	32.7M	12.9M	$50.12	150
2017 Q2	20.8M	$962M	+$143M	95.6M	25.3M	$46.28	129
2017 Q1	18M	$635M	+$202M	47.6M	14M	$35.31	116
2016 Q4	14.8M	$185M	+$2M	661K	2.98M	$12.52	96
2016 Q3	14.4M	$200M	-$703K	1.33M	1.42M	$13.85	98
2016 Q2	14.7M	$145M	-$27.8M	1.46M	837K	$9.88	98
2016 Q1	15.8M	$267M	-$13.5M	1.99M	3.28M	$16.91	104
2015 Q4	16.4M	$366M	-$11.9M	3.31M	2.62M	$22.26	111
2015 Q3	16.6M	$392M	-$216M	9.8M	9.69M	$23.59	120
2015 Q2	15.3M	$1.25B	+$183M	51.8M	133M	$81.76	150
2015 Q1	12.8M	$1.19B	+$475M	35.6M	42.8M	$92.60	139
2014 Q4	7.78M	$315M	+$169M	1.75M	2.43M	$40.44	82
2014 Q3	3.5M	$85.6M	+$3.07M			$24.46	49
2014 Q2	5.56M	$88M	+$33.7M			$15.84	43
2014 Q1	3.43M	$51.9M	+$961K			$15.12	40